Table 4.
Association of patient characteristics with positive NT-proBNP—univariate and multivariate regression analyses.
| Variable | Positive NT-proBNP (n, %) | Univariate regression analysis | Multivariate regression analysis | ||
|---|---|---|---|---|---|
| Odds ratio [confidence interval] | p-value | Odds ratio [confidence interval] | p-value | ||
| Age (> 60 years) | 97 (35) | 1.25 [0.85 to 1.84] | 0.252 | 0.93 [0.57 to 1.70] | 0.950 |
| Sex (female) | 68 (28) | 0.64 [0.44 to 0.93] | 0.021* | 1.11 [0.63 to 1.98] | 0.713 |
| SBP (> 130 mmHg) | 34 (38) | 1.34 [0.83 to 2.16] | 0.229 | 1.58 [0.85 to 2.92] | 0.148 |
| Heart rate (> 100 bpm) | 10 (38) | 1.30 [0.58 to 2.93] | 0.530 | 0.51 [0.15 to 1,76] | 0.289 |
| Cardiotoxicity | 21 (70) | 4.95 [2.21 to 11.10] | <0.001* | 3.55 [1.29 to 9.80] | 0.014* |
| Echocardiographic findings | |||||
| LVEF (< 50%) | 86 (75) | 11.62 [7.13 to 18.94] | <0.001* | 20.84 [10.67 to 40.70] | <0,001* |
| Diastolic dysfunction | 42 (43) | 1.73 [1.10 to 2.73] | 0.018* | 1.06 [0.57 to 1.96] | 0.865 |
| GLS (> −20) | 43 (58) | 3.53 [2.12 to 5.87] | <0.001* | 2.58 [1.32 to 5.02] | 0.005* |
| Comorbidities | |||||
| Coronary artery disease | 47 (56) | 1.03 [1.01 to 1.06] | 0.009* | 1.48 [0.82 to 2.65] | 0.191 |
| Hypertension | 86 (42) | 1.03 [1.01 to 1.05] | 0.008* | 1.39 [0.94 to 2.06] | 0.095 |
| Atrial fibrillation | 34 (58) | 1.03 [1.01 to 1.05] | 0.009* | 0.97 [0.47 to 1.97] | 0.927 |
| Oncological disease | |||||
| Breast cancer | 35 (30) | 0.83 [0.53 to 1.30] | 0.407 | 0.49 [0.23 to 1.08] | 0.078 |
| Malignant melanoma | 22 (17) | 0.32 [0.20 to 0.54] | <0.001* | 0.57 [0.27 to 1.23] | 0.152 |
| Leukemia | 24 (44) | 1.69 [0.96 to 3.00] | 0.071* | 0.79 [0.34 to 1.84] | 0.588 |
| Lymphoma | 13 (36) | 1.17 [0.58 to 2.38] | 0.659 | 0.53 [0.18 to 1.53] | 0.240 |
| Antineoplastic treatment | |||||
| Anthracycline | 51 (45) | 1.03 [1.01 to 10.05] | 0.008* | 1.42 [0.68 to 27.9] | 0.348 |
| Alkylation | 59 (42) | 1.03 [1.01 to 1.05] | 0.008* | 0.68 [0.34 to 1.36] | 0.275 |
| Taxane | 37 (46) | 1.03 [1.01 to 1.05] | 0.008* | 1.05 [0.70 to 1.57] | 0.828 |
| PD1 inhibitor | 25 (24) | 1.03 [1.01 to 1.05] | 0.007* | 0.50 [0.27 to 0.95] | 0.033* |
| BRAF/MEK inhibitor | 5 (19) | 0.45 [0.17 to 1.21] | <0.001* | 0.78 [0.22 to 2.76] | 0.695 |
*p < 0.05.
bpm, beats per minute; BRAF, B-Rapidly growing fibrosarcoma; GLS, global longitudinal strain; LVEF, left ventricular ejection fraction; MEK, mitogen-activated protein kinase; n, number; NT-proBNP, N-terminal pro B-type natriuretic peptide; SBP, systolic blood pressure; PD1, programmed cell death protein 1.